Get 20M+ Full-Text Papers For Less Than $1.50/day. Subscribe now for You or Your Team.

Learn More →

Long Lasting Response to the Multikinase Inhibitor Bay 43-9006 (Sorafenib) in a Heavily Pretreated Metastatic Thymic Carcinoma

Long Lasting Response to the Multikinase Inhibitor Bay 43-9006 (Sorafenib) in a Heavily... CASE REPORT Long Lasting Response to the Multikinase Inhibitor Bay 43-9006 (Sorafenib) in a Heavily Pretreated Metastatic Thymic Carcinoma Giancarlo Bisagni, MD,* Giulio Rossi, MD, PhD,† Alberto Cavazza, MD,‡ Giuliana Sartori, PhD,† Giorgio Gardini, MD,‡ and Corrado Boni, MD* 2 2 mg/m , and Ifosfamide 1200 mg/m , days 1–4, q3w) with Abstract: Metastatic thymic carcinoma is an aggressive neoplasm partial response in liver metastases and subsequent total for which multimodal therapies are often ineffective. We describe excision of left hepatic lobe. He was disease-free for 1 year here a heavily pretreated patient with advanced thymic carcinoma when pulmonary and hepatic metastases were detected. responsive to multikinases inhibitor BAY 43-9006 (Sorafenib). Of Radiofrequency ablation of the hepatic lesion followed note, a hitherto unreported c-kit missense mutation on exon 17 (D820E) by three additional PEI courses were performed with partial identified in tumor cells seems to explain the clinical response and remission and subsequent complete excision of pulmonary highlight the key role of molecular analysis in predicting efficacy of metastases. In April 2004, computed tomography (CT) de- targeted therapies even in thymic neoplasms. tected multiple lung and liver nodules and four cycles of Key Words: Thymoma, Thymic carcinoma, c-kit, CD117, http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Thoracic Oncology Wolters Kluwer Health

Long Lasting Response to the Multikinase Inhibitor Bay 43-9006 (Sorafenib) in a Heavily Pretreated Metastatic Thymic Carcinoma

Journal of Thoracic Oncology , Volume 4 (6) – Jun 1, 2009

Loading next page...
 
/lp/wolters-kluwer-health/long-lasting-response-to-the-multikinase-inhibitor-bay-43-9006-umciCwVeTW

References (9)

ISSN
1556-0864
DOI
10.1097/JTO.0b013e3181a52e25
pmid
19461405
Publisher site
See Article on Publisher Site

Abstract

CASE REPORT Long Lasting Response to the Multikinase Inhibitor Bay 43-9006 (Sorafenib) in a Heavily Pretreated Metastatic Thymic Carcinoma Giancarlo Bisagni, MD,* Giulio Rossi, MD, PhD,† Alberto Cavazza, MD,‡ Giuliana Sartori, PhD,† Giorgio Gardini, MD,‡ and Corrado Boni, MD* 2 2 mg/m , and Ifosfamide 1200 mg/m , days 1–4, q3w) with Abstract: Metastatic thymic carcinoma is an aggressive neoplasm partial response in liver metastases and subsequent total for which multimodal therapies are often ineffective. We describe excision of left hepatic lobe. He was disease-free for 1 year here a heavily pretreated patient with advanced thymic carcinoma when pulmonary and hepatic metastases were detected. responsive to multikinases inhibitor BAY 43-9006 (Sorafenib). Of Radiofrequency ablation of the hepatic lesion followed note, a hitherto unreported c-kit missense mutation on exon 17 (D820E) by three additional PEI courses were performed with partial identified in tumor cells seems to explain the clinical response and remission and subsequent complete excision of pulmonary highlight the key role of molecular analysis in predicting efficacy of metastases. In April 2004, computed tomography (CT) de- targeted therapies even in thymic neoplasms. tected multiple lung and liver nodules and four cycles of Key Words: Thymoma, Thymic carcinoma, c-kit, CD117,

Journal

Journal of Thoracic OncologyWolters Kluwer Health

Published: Jun 1, 2009

There are no references for this article.